H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
92(9):1266-7.<br />
36. Bensinger TA, Gillette PN. Hemolysis in sickle cell disease.<br />
Arch Intern Med. 1974;133:624-31.<br />
37. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertens<strong>io</strong>n<br />
as a risk factor for death in patients with sickle cell disease.<br />
N Engl J Med. 2004;350:886-95.<br />
38. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase<br />
as a b<strong>io</strong>marker of hemolysis-associated nitric oxide resistance,<br />
priapism, leg ulcerat<strong>io</strong>n, pulmonary hypertens<strong>io</strong>n, and<br />
death in patients with sickle cell disease. B<strong>lo</strong>od. 2006;107:<br />
2279-85.<br />
39. Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse<br />
WF, Ware RE. Pulmonary hypertens<strong>io</strong>n and nitric oxide deplet<strong>io</strong>n<br />
in sickle cell disease. B<strong>lo</strong>od. 2010;116(5):687-92.<br />
40. Hebbel RP. Reconstructing sickle cell disease: a data-based<br />
analysis of the “hyper-hemolysis paradigm” for pulmonary<br />
hypertens<strong>io</strong>n from the perspective of evidence-based medicine.<br />
Am J Hematol., 2011;86(2):123-154.<br />
41. Wagener FA, Eggert A, Boerman OC, et al. Heme is a potent<br />
inducer of inflammat<strong>io</strong>n in mice and is counteracted by heme<br />
oxygenase. B<strong>lo</strong>od. 2001;98:1802-11.<br />
42. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G.<br />
Improved survival in homozygous sickle cell disease: lessons<br />
from a cohort study. Br Med J. 1995;311:1600-2.<br />
43. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell<br />
disease. Rates and risk factors. N Engl J Med. 1991;325:11-6.<br />
44. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell<br />
disease: life expectancy and risk factors for early death. N<br />
Engl J Med. 1994;330:1639-44.<br />
45. McClish DK, Smith WR, Dahman BA, et al. Pain site frequency<br />
and <strong>lo</strong>cat<strong>io</strong>n in sickle cell disease. Pain. 2009;145(1-2):246-51.<br />
46. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes<br />
of the acute chest syndrome in sickle cell disease.<br />
Nat<strong>io</strong>nal Acute Chest Syndrome Study Group. N Engl J Med.<br />
2000;342:1855-65.<br />
47. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular<br />
accidents in sickle cell disease: rates and risk factors. B<strong>lo</strong>od.<br />
1998;91(1):288-94.<br />
48. Smith WR, Bovbjerg VE, Penberthy LT, et al. Understanding pain<br />
and improving management of sickle cell disease: the PiSCES<br />
study. J Natl Med Assoc. 2005;97(2):183-93.<br />
49. Miller ST, Sleeper LA, Pege<strong>lo</strong>w CH, et al. Predict<strong>io</strong>n of adverse<br />
outcomes in children with sickle cell disease. N Engl J Med. 2000;<br />
342:83-9.<br />
50. Frenette PS. Sickle cell vaso-occlus<strong>io</strong>n: heterotypic, multicellular<br />
aggregat<strong>io</strong>ns driven by leukocyte adhes<strong>io</strong>n. Microcirculat<strong>io</strong>n.<br />
2004;11(2):167-77.<br />
51. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved<br />
survival of children and adolescents with sickle cell disease.<br />
B<strong>lo</strong>od. 2010;115:3447-52.<br />
52. Sebastiani P, So<strong>lo</strong>vieff N, Hartley SW, et al. Genetic modifiers of<br />
the severity of sickle cell anemia identified through a genomewide<br />
associat<strong>io</strong>n study. Am J Hematol. 2010;85(1):29-35.<br />
53. Van Beers EJ, van Tuijn CF, Nieuwkerk PT, Friederich PW,<br />
Vranken JH, Biemond BJ. Patient-controlled analgesia versus<br />
continous infus<strong>io</strong>n of morphine during vaso-occlusive crisis in<br />
sickle cell disease, a randomized controlled trial. Am J Hematol.<br />
2007;82(11):955-60.<br />
54. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous<br />
methylpredniso<strong>lo</strong>ne therapy for pain in children and adolescents<br />
with sickle cell disease. N Engl J Med. 1994;330(11):773-7.<br />
55. Strouse JJ, Takemoto CM, Keefer JR, Kato GJ, Casella JF.<br />
Corticosteroids and increased risk of readmiss<strong>io</strong>n after acute<br />
chest syndrome in children with sickle cell disease. Pediatr B<strong>lo</strong>od<br />
Cancer. 2008;50(5):1006-12.<br />
56. Solanki DL. Sickle cell anemia, oxygen treatment, and anaemic<br />
crisis. Br Med J. 1983;287:725-6.<br />
57. Lane PK, Embury SH, Toy PT. Oxygen induced marrow red<br />
cell hypoplasia leading to transfus<strong>io</strong>n in sickle painful crisis.<br />
Am J Hematol. 1988;27:67-8.<br />
58. Adams-Graves P, Kedar A, Koshy M, et al. RheothRx (po<strong>lo</strong>xamer<br />
188) inject<strong>io</strong>n for the acute painful episode of sickle cell<br />
disease: a pi<strong>lo</strong>t study. B<strong>lo</strong>od. 1997;90(5):2041-6.<br />
59. Ataga KI, Smith WR, DeCastro LM, et al. Efficacy and safety<br />
of the Gardos Channel b<strong>lo</strong>cker, senicapoc (ICA-17043), in<br />
patients with sickle cell anemia. B<strong>lo</strong>od. 2008;111(8):3991-7.<br />
60. Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous<br />
immunog<strong>lo</strong>bulins reverse acute vaso-occlusive crises in sickle<br />
cell mice through rapid inhibit<strong>io</strong>n of neutrophil adhes<strong>io</strong>n.<br />
B<strong>lo</strong>od. 2008;111(2):915-23.<br />
London, United Kingdom, June 9-12, 2011<br />
61. Kaul DK, Tsai HM, Liu XD, et al. Monoc<strong>lo</strong>nal antibodies to<br />
alphaVbeta3 (7E3 and LM609) inhibit sickle red b<strong>lo</strong>od cellendothelium<br />
interact<strong>io</strong>ns induced by platelet-activating factor.<br />
B<strong>lo</strong>od. 2000;95:368-74.<br />
62. Finnegan EM, Barabino GA, Liu XS, Chang HY, Jonczyk A,<br />
Kaul DK. Small-molecule cyclic alpha V beta 3 antagonists<br />
inhibit sickle red cell adhes<strong>io</strong>n to vascular endothelium and<br />
vasooclus<strong>io</strong>n. Am J Phys<strong>io</strong>l. 2007;293(2):H1038-45.<br />
63. Chang J, Patton JT, Sarkar A, Ernst B, Magnani JL, Frenette PS.<br />
GMI-1070, a novel pan-selectin antagonist, reverses acute vascular<br />
occlus<strong>io</strong>ns in sickle cell mice. B<strong>lo</strong>od. 2010;116(10):1779-86.<br />
64. So<strong>lo</strong>vey AA, So<strong>lo</strong>vey AN, Harkness J, Hebbel RP. Modulat<strong>io</strong>n<br />
of endothelial cell activat<strong>io</strong>n in sickle cell disease: a pi<strong>lo</strong>t study.<br />
B<strong>lo</strong>od. 2001;97(7):1937-41.<br />
65. Head CA, Swerd<strong>lo</strong>w P, McDade WA, et al. Beneficial effects<br />
of nitric oxide breathing in adult patients with sickle cell crisis.<br />
Am J Hematol. 2010;85(10):800-2.<br />
66. Hebbel RP, Vercel<strong>lo</strong>tti GM, Pace BS, et al. The HDAC<br />
inhibitors trichostatin A and suberoylanilide hydroxamic acid<br />
exhibit multiple modalities of benefit for the vascular b<strong>io</strong><strong>lo</strong>gy<br />
of sickle transgenic mice. B<strong>lo</strong>od. 2010;115(12):2483-90.<br />
67. Hebbel RP, Vercel<strong>lo</strong>tti G, Nath KA. A systems b<strong>io</strong><strong>lo</strong>gy considerat<strong>io</strong>n<br />
of the vascu<strong>lo</strong>pathy of sickle cell anemia: the need for<br />
multi-modality chemo-prophylaxis. Curr Drug Targets Card<strong>io</strong>vasc<br />
Haematol Disord. 2009;9(4):271-92.<br />
68. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects<br />
on hemog<strong>lo</strong>bin F product<strong>io</strong>n in patients with sickle cell anemia.<br />
B<strong>lo</strong>od. 1992;79(10):2555-65.<br />
69. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea<br />
on the frequency of painful crises in sickle cell anemia.<br />
Investigators of the Multicenter Study of Hydroxyurea in<br />
Sickle Cell Anemia. N Engl J Med. 1995; 332:1317-22.<br />
70. Kinney TR, Helms RW, O’Branski EE, et al. Safety of hydroxyurea<br />
in children with sickle cell anemia: results of the HUG-<br />
KIDS study, a phase I/II Pediatric Hydroxyurea Group. B<strong>lo</strong>od.<br />
1999;94(5):1550-4.<br />
71. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE.<br />
A two-year pi<strong>lo</strong>t trial of hydroxyurea in very young children<br />
with sickle-cell anemia. J Pediatr. 2001;139(6):790-6.<br />
72. Ware RE. How I use hydroxyurea to treat young patients with<br />
sickle cell anemia. B<strong>lo</strong>od. 2010;115(26):5300-11.<br />
73. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy<br />
decreases the in vitro adhes<strong>io</strong>n of sickle erythrocytes to<br />
thrombospondin and laminin. Br J Haematol. 2000;109:322-7.<br />
74. Gambero S, Canalli AA, Traina F, et al. Therapy with hydroxyurea<br />
is associated with reduced adhes<strong>io</strong>n molecule gene and<br />
protein express<strong>io</strong>n in sickle red cells with a concomitant reduct<strong>io</strong>n<br />
in adhesive properties. Eur J Haematol. 2007;78(2):144-51.<br />
75. Cartron JP, El<strong>io</strong>n J. Erythroid adhes<strong>io</strong>n molecules in sickle cell disease:<br />
effect of hydroxyurea. Trans Clin B<strong>io</strong>l. 2008;15(1-2):39-50.<br />
76. Odievre MH, Bony V, Benkerrou M, et al. Modulat<strong>io</strong>n of erythroid<br />
adhes<strong>io</strong>n receptor express<strong>io</strong>n by hydroxyurea in children<br />
with sickle cell disease. Haemato<strong>lo</strong>gica. 2008;93:502-10.<br />
77. Styles LA, Lubin B, Vichinsky E, et al. Decrease of very late<br />
activat<strong>io</strong>n antigen-4 and CD36 on reticu<strong>lo</strong>cytes in sickle cell<br />
patients treated with hydroxyurea. B<strong>lo</strong>od. 1997;89:2554-9.<br />
78. Haynes J Jr, Obiako B, Hester RB, Baliga BS, Stevens T.<br />
Hydroxyurea attenuates activated neutrophil-mediated sickle<br />
erythrocyte membrance phosphatidylserine exposure and<br />
adhes<strong>io</strong>n to pulmonary vascular endothelium. Am J Phys. 2008;<br />
294(1):H379-85.<br />
79. Laurance S, Pellay FX, Dossou-Yovo OP, et al. Hydroxycarbamide<br />
stimulates the product<strong>io</strong>n of proinflammatory cytokines by<br />
endothelial cells: relevance to sickle cell disease. Pharmacogenetics<br />
Genomics. 2010;20(4):257-68.<br />
80. Lapoumeroulie C, Benkerrou M, Odievre MH, et al. Decreased<br />
plasma endothelin-1 levels in children with sickle cell disease<br />
treated with hydroxyurea. Haemato<strong>lo</strong>gica. 2005;90:401-3.<br />
81. Lanaro C, Franco-Penteado CF, Albuqueque DM, Saad ST,<br />
Conran N, Costa FF. Altered levels of cytokines and inflammatory<br />
mediators in plasma and leukocytes of sickle cell anemia<br />
patients and effects of hydroxyurea therapy. J Leuk B<strong>io</strong>l. 2009;<br />
85(2):235-42.<br />
82. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia:<br />
what have we learned and what quest<strong>io</strong>ns remain? Curr Opin<br />
Hematol., 2011;18(3):158-165.<br />
Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1) | 329 |